Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$72.29M |
$1.36
+9.68%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$72.08M |
$1.71
+3.64%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$71.57M |
$7.77
-1.27%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$70.46M |
$1.07
-1.38%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$69.84M |
$0.71
-1.67%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$68.67M |
$1.24
+4.66%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$67.55M |
$5.33
+3.19%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$66.77M |
$1.25
-0.40%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$66.27M |
$1.27
+4.51%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$65.31M |
$1.78
+2.30%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$64.13M |
$1.55
-2.52%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$63.10M |
$19.38
+5.70%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$60.68M |
$13.21
+0.69%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$58.98M |
$1.48
+0.68%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$58.96M |
$9.42
+1.18%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$56.08M |
$12.35
-0.40%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$55.36M |
$9.34
-9.58%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$55.11M |
$0.57
-1.85%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$54.53M |
$4.63
-0.32%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$53.07M |
$2.67
+13.83%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$52.59M |
$4.37
-1.13%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$51.32M |
$2.15
-4.22%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$51.03M |
$3.81
+0.26%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$49.90M |
$1.07
+7.72%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$49.43M |
$1.57
+2.27%
|
Showing page 18 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
